<p><a href="https://www.mediapen.com/news/view/914733" target="_top" class="ke-link">"자금력 확보"...제약·바이오, M&A 전략으로 활로 모색 (mediapen.com)</a></p><div class="figure-open" contenteditable="false" data-ke-type="opengraph" data-ke-align="alignCenter" data-og-type="website" data-og-title=""자금력 확보"...제약·바이오, M&A 전략으로 활로 모색" data-og-description="[미디어펜=김견희 기자]최근 국내 제약·바이오 기업들이 연구개발(R&D) 및 사업에 필요한 자금을 확보하기 위해 인수합병(M&A) 전략을 짜고 있다. 올해 초 인수전" data-og-host="mediapen.com" data-og-source-url="https://www.mediapen.com/news/view/914733" data-og-url="https://mediapen.com/news/view/914733" data-og-image="https://scrap.kakaocdn.net/dn/JN3kp/hyVVF6rLWH/9RzBtHfttzY0kHdlu4GKn0/img.jpg?width=600&height=400&face=0_0_600_400,https://scrap.kakaocdn.net/dn/ca44IU/hyVVMR2D0G/1SSvqkYN8s73B5k4vcwYX0/img.jpg?width=600&height=400&face=0_0_600_400,https://scrap.kakaocdn.net/dn/dLs0YZ/hyVVKfEqoh/tqVM81yM5RS1appgylvjuK/img.jpg?width=600&height=400&face=0_0_600_400"><a href="https://www.mediapen.com/news/view/914733" target="_blank" data-source-url="https://www.mediapen.com/news/view/914733"><div class="og-image"><img src="https://scrap.kakaocdn.net/dn/JN3kp/hyVVF6rLWH/9RzBtHfttzY0kHdlu4GKn0/img.jpg?width=600&height=400&face=0_0_600_400,https://scrap.kakaocdn.net/dn/ca44IU/hyVVMR2D0G/1SSvqkYN8s73B5k4vcwYX0/img.jpg?width=600&height=400&face=0_0_600_400,https://scrap.kakaocdn.net/dn/dLs0YZ/hyVVKfEqoh/tqVM81yM5RS1appgylvjuK/img.jpg?width=600&height=400&face=0_0_600_400" alt="" xxonerror="this.src="//img1.kakaocdn.net/thumb/C200x200/?fname=https%3A%2F%2Ft1.daumcdn.net%2Fcafe_image%2Fcafe_meta_image_190529.png""></div><div class="og-text"><p class="og-title">"자금력 확보"...제약·바이오, M&A 전략으로 활로 모색</p><p class="og-desc">[미디어펜=김견희 기자]최근 국내 제약·바이오 기업들이 연구개발(R&D) 및 사업에 필요한 자금을 확보하기 위해 인수합병(M&A) 전략을 짜고 있다. 올해 초 인수전</p><p class="og-host">mediapen.com</p></div></a></div><p> </p>
<!-- -->
